Immune Monitoring for CMV in Transplantation
- 634 Downloads
Purpose of Review
Immune monitoring to determine when and how the recovery of cytomegalovirus (CMV)-specific T-cells occurs post-transplantation may help clinicians to risk stratify individuals at risk of complications from CMV. We aimed to review all recent clinical studies using CMV immune monitoring in the pre- and post-transplant setting including the use of recently developed standardized assays (Quantiferon-CMV and the CMV ELISPOT) to better understand in whom, when, and how immune monitoring is best used.
Pre-transplant assessment of CMV immunity in solid-organ transplant recipients where CMV seropositive recipients had undetectable cell-mediated responses despite past immunity has shown that they are at a much higher risk of developing CMV reactivation. Post-transplant CMV immune monitoring can guide (shorten or prolong) the duration of antiviral prophylaxis, identify recipients at risk of post-prophylaxis CMV disease, and predict recurrent CMV reactivation.
Thus, CMV immune monitoring, in addition to current clinical and DNA-based monitoring for CMV, has the potential to be incorporated into routine clinical care to better improve CMV management in both the stem and solid-organ transplant population.
KeywordsCytomegalovirus Solid-organ transplantation Stem-cell transplantation CMV-specific immunity Immune monitoring Quantiferon-CMV ELISPOT
Compliance with Ethical Standards
Conflict of Interest
Dr. Manuel has received research grants from Lophius Biosciences GmbH and from Qiagen. Dr. Yong and Dr. Lewin declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 2.Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2010;10(5):1228–37.CrossRefGoogle Scholar
- 3.Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2004;4(4):611–20.CrossRefGoogle Scholar
- 4.Matter-Walstra KW, Greiner M, Cusini A, Schiesser M, Ledergerber B, Fehr T, et al. Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. Transpl Infect Dis. 2015;17(3):342–9.CrossRefPubMedGoogle Scholar
- 5.Manuel O, Kralidis G, Mueller NJ, Hirsch HH, Garzoni C, van Delden C, et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(9):2402–10.CrossRefGoogle Scholar
- 6.Navarro D, San-Juan R, Manuel O, Gimenez E, Fernandez-Ruiz M, Hirsch HH, et al. Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: an ESGICH survey. Transpl Infect Dis. 2017;19:e12773. https://doi.org/10.1111/tid.12773.
- 11.Martin-Gandul C, Perez-Romero P, Gonzalez-Roncero FM, Berdaguer S, Gomez MA, Lage E, et al. Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients. J Inf Secur. 2014;69(5):500–6.Google Scholar
- 16.Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2013;56(6):817–24.CrossRefGoogle Scholar
- 20.Tey SK, Kennedy GA, Cromer D, Davenport MP, Walker S, Jones LI, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV(R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS One. 2013;8(10):e74744.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Abate D, Saldan A, Mengoli C, Fiscon M, Silvestre C, Fallico L, et al. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients. J Clin Microbiol. 2013;51(8):2501–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Nesher L, Shah DP, Ariza-Heredia EJ, Azzi JM, Siddiqui HK, Ghantoji SS, et al. Utility of the enzyme-linked Immunospot interferon-gamma-release assay to predict the risk of cytomegalovirus infection in hematopoietic cell transplant recipients. J Infect Dis. 2016;213(11):1701–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Borchers S, Luther S, Lips U, Hahn N, Kontsendorn J, Stadler M, et al. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2011;13(3):222–36.CrossRefPubMedGoogle Scholar
- 30.Cantisan S, Lara R, Montejo M, Redel J, Rodriguez-Benot A, Gutierrez-Aroca J, et al. Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(3):738–45.CrossRefGoogle Scholar
- 31.Bestard O, Lucia M, Crespo E, Van Liempt B, Palacio D, Melilli E, et al. Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2013;13(7):1793–805.CrossRefGoogle Scholar
- 32.Lucia M, Crespo E, Melilli E, Cruzado JM, Luque S, Llaudo I, et al. Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;59(11):1537–45.CrossRefGoogle Scholar
- 35.Westall GP, Cristiano Y, Peleg AY, Paraskeva M, Levvey B, Whitford H, et al. A study of QuantiFERON-CMV-directed CMV prophylaxis versus standard-of-care to reduce late CMV reactivation in patients undergoing lung transplantation. 37th International Society for Heart and Lung Transplantation Annual Meeting; San Diego, California 2017.Google Scholar
- 43.Mena-Romo JD, Perez Romero P, Martin-Gandul C, Gentil MA, Suarez-Artacho G, Lage E, et al. CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy. J Inf Secur. 2017;75(4):336–45.Google Scholar
- 46.George B, Kerridge IH, Gilroy N, Huang G, Hertzberg MS, Bradstock KF, et al. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis. 2012;14(2):141–8.CrossRefPubMedGoogle Scholar
- 47.Navarro D, Amat P, de la Camara R, Lopez J, Vazquez L, Serrano D, et al. Efficacy and safety of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic stem cell transplant recipients. Open Forum Infect Dis. 2016;3(2):ofw107.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Solano C, Benet I, Remigia MJ, de la Camara R, Munoz-Cobo B, Costa E, et al. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience. Transplantation. 2011;92(4):e17–20.CrossRefPubMedGoogle Scholar
- 51.Hoegh-Petersen M, Roa L, Liu Y, Zhou F, Ugarte-Torres A, Louie P, et al. Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors. Cytotherapy. 2012;14(2):194–204.CrossRefPubMedGoogle Scholar